Digestive Diseases and Sciences

, Volume 52, Issue 3, pp 742–748 | Cite as

Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome

  • Eric Esrailian
  • Eugene R. Pantangco
  • Namgyal L. Kyulo
  • Ke-Qin Hu
  • Bruce A. RunyonEmail author
Original Article


Type 1 hepatorenal syndrome (HRS) can be a rapidly fatal consequence of liver failure. Recent studies have utilized vasoconstrictor therapies to combat splanchnic vasodilatation. We aimed to evaluate the efficacy of a promising treatment for type 1 HRS. We compared the survival of HRS patients who received octreotide and midodrine treatment at Rancho Los Amigos Medical Center with a concurrent untreated control group of HRS patients who did not receive this treatment. Of the 81 patients, 60 were treated with octreotide/midodrine and 21 were controls. Mortality was significantly lower in the treatment group (43%) than in the controls (71%; P < 0.05). Furthermore, 24 study patients (40%) had a sustained reduction of serum creatinine compared with only 2 controls (10%; P < 0.05). This large retrospective study suggests that octreotide/midodrine treatment appears to improve 30-day survival. A randomized, controlled trial is the next important step toward evaluating this treatment modality.


Cirrhosis Renal failure Hepatorenal syndrome Ascites Portal hypertension 



This paper is dedicated to Dr. Telfer B. Reynolds, who spent his distinguished career studying, teaching about, and caring for patients with liver failure and fluid and electrolyte imbalance. His influence on the authors and on this study cannot be quantified.


  1. 1.
    v. Frerichs T (1877) Tratado práctico de las enfermedades del hígado, de los vasos hepáticos y de las vias biliares. Librería Extranjera y Nacional, científica y Literaria, Madrid, pp 362–353Google Scholar
  2. 2.
    Flint A (1863) Clinical report on hydro-peritoneum based on an analysis of forty-six cases. Am J Med Sci 45:306–339CrossRefGoogle Scholar
  3. 3.
    Hecker R, Sherlock S (1956) Electrolyte and circulatory changes in terminal liver failure. Lancet 2:1221–1225Google Scholar
  4. 4.
    Arroyo V, Ginés P, Gerbes A, Dudley FJ, Gentillini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164–176PubMedCrossRefGoogle Scholar
  5. 5.
    Ginés A, Escorsell A, Ginés P, Salo J, Jimenez W, Inglada L, Navasa M, Claria J, Rimola A, Arroyo V (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105:229–236PubMedGoogle Scholar
  6. 6.
    Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL, Garcia-Plaza A, Leal J (1989) Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97:1304–1312PubMedGoogle Scholar
  7. 7.
    Arroyo V, Guevara M, Ginés P (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122:1658–1676PubMedCrossRefGoogle Scholar
  8. 8.
    Wong F, Blendis L (2001) New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 34:1242–1251PubMedCrossRefGoogle Scholar
  9. 9.
    Gonwa TA, Morris CA, Goldstein RM, Husbert BS, Klintmalm GB (1991) Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 91:428–430CrossRefGoogle Scholar
  10. 10.
    Gonwa TA, Klintmalm GB, Jennings LS, Goldstein RM, Husberg B (1995) Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59:361–365PubMedGoogle Scholar
  11. 11.
    Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE (1973) Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Engl J Med 289:1155–1159PubMedCrossRefGoogle Scholar
  12. 12.
    Ortega R, Ginés P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948PubMedGoogle Scholar
  13. 13.
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923–930PubMedCrossRefGoogle Scholar
  14. 14.
    Duhamel C, Mauillon J, Berkelmans I, Bourienne A, Tranvouez JL (2000) Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 95:2984–2985PubMedCrossRefGoogle Scholar
  15. 15.
    Gulberg V, Bilzer M, Gerbes AL (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30:870–875PubMedCrossRefGoogle Scholar
  16. 16.
    Angeli P, Volpin R, Gerunda G, Craighero R, Romero P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffel-Faccioli A, Gatta A (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690–1697PubMedCrossRefGoogle Scholar
  17. 17.
    Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563–572PubMedCrossRefGoogle Scholar
  18. 18.
    Cárdenas A, Ginés P, Rodés J (2003) Renal complications. In: Schiff ER, Sorrell MF, Maddrey WC (eds) Schiff's diseases of the liver. 9th ed. Lippincott Williams & Wilkins, Philadelphia, pp 497–509Google Scholar
  19. 19.
    Dagher L, Patch D, Marley R, Moore K, Burroughs A (2000) Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 14:515–521PubMedCrossRefGoogle Scholar
  20. 20.
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119:1637–1648PubMedCrossRefGoogle Scholar
  21. 21.
    Wong F, Pantea L, Sniderman K (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40(1):55–64PubMedCrossRefGoogle Scholar
  22. 22.
    Afessa B, Kublis PS (2000) Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol 95:484–489PubMedCrossRefGoogle Scholar
  23. 23.
    Navasa M, Rodes J (1997) Management of ascites in the patient with portal hypertension with emphasis on spontaneous bacterial peritonitis. Semin Gastrointest Dis 8:200–209PubMedGoogle Scholar
  24. 24.
    Papper S (1983) The hepatorenal syndrome. In: Epstein M (ed) The kidney in liver disease. 2nd ed. Elsevier Biomedical, New York, pp 87–106Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Eric Esrailian
    • 1
  • Eugene R. Pantangco
    • 1
  • Namgyal L. Kyulo
    • 2
  • Ke-Qin Hu
    • 2
  • Bruce A. Runyon
    • 1
    • 3
    Email author
  1. 1.University of Southern California Liver Unit at Rancho Los Amigos Medical CenterDowneyUSA
  2. 2.Division of Gastroenterology/HepatologyUniversity of CaliforniaIrvine, OrangeUSA
  3. 3.Liver ServiceLoma Linda University Medical CenterLoma LindaUSA

Personalised recommendations